Enzon’s PEG-L-asparaginase
Executive Summary
NCI's Division of Cancer Treatment will collaborate with the company on clinical trials with the modified asparaginase in the treatment of acute lymphoblastic leukemia, Enzon announced Dec. 18. "With the help of NCI, we hope to vastly broaden the accessibility of PEG-L-asparaginase to patients who are allergic to the commonly used E. coli derived enzyme as well as to newly diagnosed patients as part of firstline treatment regimens," Enzon said. Last month, the firm said a PLA for PEG-L-asparaginase is ready to be filed at FDA.